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The Met receptor in normal physiology and disease
Th   e Met tyrosine kinase receptor for hepatocyte growth 
factor (HGF) fosters invasive growth, a complex 
physiological program that implies the concerted 
activation of cell proliferation, survival, invasion and 
angiogenesis [1-4] (Figure  1). Met-regulated invasive 
growth plays important roles under physiological condi-
tions – during development and tissue regeneration – 
and controls cancer invasion and metastasis [3,5].
In embryonic life, Met is expressed by epithelial and 
myoblast progenitors, whereas HGF is secreted by 
mesenchymal cells [6,7]. Th  e paracrine stimulation of 
Met by HGF is essential for placenta and liver develop-
ment and for migration of myoblast precursors [8-10]. In 
adulthood, the invasive growth program triggered by Met 
activation, when reversibly executed in space and time, is 
commonly associated with organ repair [11,12]. In 
contrast, derailment of Met-dependent signals promotes 
the progression and invasiveness of a large number of 
human cancers. In this context, Met hyperactivation is 
usually due to transcriptional upregulation, which is in 
turn induced by oncogenic alterations or micro-
environmental stimuli. In a fraction of cases, constitutive 
ﬁ  ring of Met can be caused by genomic ampliﬁ  cation, by 
point mutations, or by the presence of ligand autocrine 
loops [13-16]. High levels of HGF and/or Met over-
expression correlate with the aggressive phenotype of 
diﬀ   erent carcinomas, including those of the prostate, 
stomach, pancreas, thyroid and breast [17-20].
The Met receptor in breast cancer
In past years, a large number of clinical studies have 
described Met-receptor overexpression and pathway 
hyperactivation in tissues derived from breast cancer 
patients, and have found a strong relationship between 
high HGF/Met signaling and tumor progression 
(Table 1). Indeed, the HGF content in breast tumor tissue 
correlates with the aggressive phenotype, being higher in 
invasive ductal carcinomas than in ductal carcinomas in 
situ and benign hyperplasia [21,22]. In normal mammary 
tissue HGF is expressed by stromal cells surrounding the 
epithelial compartment, whereas in cancer the ligand can 
be produced de novo by carcinoma cells that also express 
the receptor, thus generating an autocrine loop that 
predicts poor prognosis [16]. Moreover, in many cases 
HGF and Met are co-expressed in correspondence of the 
advancing margins of mammary tumors, a ﬁ  nding that 
goes along with high histological grade and high 
proliferative index [23]. In axillary lymph node-negative 
patients, Met overexpression is signiﬁ  cantly associated 
with reduced survival, with a 5-year survival rate of 62% 
compared with 97% of Met low-expressing patients. Th  e 
follow-up of these patients revealed that in many cases 
Met expression was negligible at the time of diagnosis 
but increased in late recurrences, thus suggesting a 
possible selection of Met-overexpressing clones in relapse 
and metastasis [24].
Abstract
Recent fi  ndings suggest the involvement of the MET 
oncogene, encoding the tyrosine kinase receptor for 
hepatocyte growth factor, in the onset and progression 
of basal-like breast carcinoma. The expression profi  les 
of basal-like tumors – but not those of other breast 
cancer subtypes – are enriched for gene sets that 
are coordinately over-represented in transcriptional 
signatures regulated by Met. Consistently, tissue 
microarray analyses have revealed that Met 
immunoreactivity is much higher in basal-like cases of 
human breast cancer than in other tumor types. Finally, 
mouse models expressing mutationally activated 
forms of Met develop a high incidence of mammary 
tumors, some of which exhibit basal characteristics. The 
present review summarizes current knowledge on the 
role and activity of Met in basal-like breast cancer, with 
a special emphasis on the correlation between this 
tumor subtype and the cellular hierarchy of the normal 
mammary gland.
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© 2010 BioMed Central LtdClinical data are supported by animal models of Met-
driven mammary tumorigenesis: transgenic mice in which 
HGF has been speciﬁ   cally targeted to the mammary 
epithelium using the Whey-acidic-protein promoter 
display a hyperplastic ductal tree with multi  focal invasive 
tumors [25]. Similarly, primary cultures of mammary cells 
overexpressing Met develop nonprogres  sive neoplasms 
upon orthotopic implantation in recipient mice; such 
lesions are able to progress to adeno  carcinomas when the 
proto-oncogene Myc is ectopically overexpressed 
together with Met [26].
Molecular classifi  cation of human breast cancer 
recalls the cellular hierarchy of the normal 
mammary gland
Human breast cancer is a heterogeneous disease that 
comprises a variety of pathologies with diﬀ  erent histo-
logical features and clinical outcomes. On the basis of 
Figure 1. Structure and signaling machinery of the Met receptor. Met is an α/β heterodimer formed by a completely extracellular α subunit 
and a transmembrane β subunit that contains the tyrosine kinase activity. The extracellular region of Met encompasses a large Sema domain – 
which spans the α subunit and part of the β subunit, folding into a β-propeller structure – a cysteine-rich domain and four repeats of an unusual 
type of immunoglobulin-like domain. The intracellular portion of Met includes the kinase domain – with two catalytic tyrosines (Tyr1234 and 
Tyr1235) that enhance the receptor enzymatic activity following transphosphorylation – and key tyrosine residues in the carboxy-terminal tail 
(Tyr1349 and Tyr1356). Phosphorylation of these distal tyrosines creates docking sites for several interactors, many of which are schematized here. 
Recruitment of these signaling eff  ectors activates downstream pathways that together enable biological execution of the invasive growth process. 
The Ras-Erk/mitogen-activated protein kinase (MAPK) cascade launches a program of transcriptional modulation that involves changes in the 
expression of cell-cycle regulators and extracellular matrix proteinases. Ras also stimulates the Rac1/Cdc42-PAK pathway, which, together with the 
Gab1–Crk–C3G–Rap1 axis, regulates the activity of cytoskeletal and adhesion molecules such as cadherins, Arp, N-WASP, paxillin, integrins and focal 
adhesion kinase. The Gab1–phosphoinositide 3-kinase (PI3K)–Akt pathway encourages cell survival by inhibiting the proapoptotic molecule Bad 
and the apopototic eff  ector caspase 9.
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analysis of a large set of tumor samples, Sorlie and 
colleagues deﬁ   ned a new molecular classiﬁ  cation  of 
human breast cancers [27]. According to this classiﬁ    ca-
tion, breast tumors have been clustered into ﬁ  ve diﬀ  erent 
subtypes: luminal A, luminal B, Her2-overexpressing, 
normal-like and basal-like. Th  is  classiﬁ  cation reﬂ  ects the 
characteristics of the cell populations that are present in 
the normal epithelium of the mammary gland. In fact, 
besides highlighting the molecular heterogeneity of 
breast tumor subtypes, the transcriptional proﬁ  les 
revealed a molecular/phenotypic connection between the 
transformed cells and the normal epithelial counterpart. 
Based on this observation, it has been proposed that the 
diﬀ  erent types of breast cancer have their cell of origin in 
the diﬀ  erent subpopulations that constitute the normal 
mammary gland under physiological conditions.
The cell hierarchy of the normal mammary gland
Th  e mature mammary epithelium is composed of three 
main epithelial cell types: the basal/myoepithelial cells, 
which line the outer side of the ducts; and the luminal 
cells, which are further distinguished into ductal and 
alveolar elements and form the inner side of the ducts 
and the alveoli, respectively. According to molecular 
proﬁ  ling, it is assumed that the luminal subtype arises 
from cells belonging to the luminal lineage, whilst the 
basal subtype is supposed to derive from less diﬀ  er  en-
tiated cells of the gland – such as stem/progenitor cells – 
that are normally located within the basal/myoepithelial 
compartment and exhibit basal phenotypic markers.
Th   e epithelial cells of the mammary gland are 
organized in a hierarchical manner, with stem cells and 
progenitor cells giving rise to all the diﬀ  erent lineages 
that are present in the mature gland. Th   e stem cells, also 
called mammary repopulating units, are capable of self-
renewal and generate all of the cellular types that make 
up the mammary gland [28]. Th   e existence of a stem cell 
population has been postulated for a long time because 
of the ability of the mammary gland to go through several 
cycles of proliferation and involution during pregnancies, 
and due to the fact that the transplantation of mammary 
fragments into the fat pad of receiving animals is 
suﬃ   cient to form a mature mammary tree [29,30]. Th  e 
immediate progeny of stem cells identiﬁ  es the compart-
ment of progenitors, which is composed of actively 
proliferating cells endowed with a limited diﬀ  erentiation 
potential. Progenitor cells are also called mammary 
colony-forming units because of their ability to eﬃ   ciently 
generate clonal aggregates when cultured in vitro [31].
Th  e recent identiﬁ   cation of surface markers charac-
teristic of the distinct subpopulations, from undiﬀ  er  en-
tiated cells to mature cells, allowed their prospective 
isolation and biological characterization. Two indepen  dent 
Table 1. Summary of HGF/Met alterations in breast cancer
Reference Observations/lesions  Clinical/biological  aspects
Yao and colleagues [21]  High levels of HGF in breast tumor tissue  Invasive ductal carcinomas
Tuck and colleagues [16]  HGF/Met autocrine loop in tumor cells  Co-localization at the advancing margins of the tumors
Jin and colleagues [22]  High levels of HGF and c-Met overexpression in breast tissue  Invasive ductal carcinomas
Camp and colleagues [24]   Met overexpression  Reduced survival, relapse and metastatic dissemination
Edakuni and colleagues [23]   Met overexpression  High histological grade, proliferative index, advancing 
   margins
Kang and colleagues [82]  High levels of Met and HGF in node-negative breast cancer  Tumor progression and poor patient outcome
Lengyel and colleagues [83]  Met overexpression in node-positive breast cancer  Disease progression and decrease in disease-free 
   survival
Charafe-Jauff  re and colleagues [43]   Met overexpression in breast cancer cell lines  Basal-like phenotype
Lindemann and colleagues [84]  Imbalance in Met expression between tumor and normal   Aggressive ductal carcinoma in situ
 tissue 
Eichbaum and colleagues [85]  High HGF serum levels  Liver metastatic colonization from breast cancer
Garcia and colleagues [45]   Met overexpression in tissue microarrays  Poor prognosis, basal-like phenotype
Finkbeiner and colleagues [49]   Transcriptional upregulation of Met  Anchorage-independent growth of basal-like breast 
   cancer  cells
Smolen and colleagues [65]   Met amplifi  cation in a Brca1-p53 mouse model of breast   Mouse mammary tumor progression
 cancer
Ponzo and colleagues [53]   MMTV-Met mutant transgenic mice  Heterogeneous mammary tumors, basal-like 
   phenotype
Graveel and colleagues [52]   Met mutant knock-in mice  Mammary tumors associated with basal-like 
   phenotype
HGF, hepatocyte growth factor; MMTV, mouse mammary tumor virus promoter.
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populating units and progenitor cells on the basis of the 
diﬀ   erential expression of the surface markers CD24, 
CD49f and CD29. Stingl and colleagues identiﬁ  ed mam-
mary repopulating units on the basis of a CD24+CD49fhigh 
phenotype, while Shackleton and coworkers deﬁ  ned the 
stem cell subpopulation as Lin–CD24+CD29high [31,32]. 
Both groups demonstrated the ability of these cells to self-
renew and to generate a completely functional mammary 
gland even after transplantation of one single cell. A subset 
of progenitors committed to the luminal lineage was 
isolated based on the expression of CD61 and low levels of 
CD133 and Sca1. Th  ese cells can terminally diﬀ  erentiate 
into mature luminal cells, which lose CD61 expression and 
increase expression of CD133 and Sca1 [33,34].
Mammary epithelial subpopulations and types of breast 
cancer
As mentioned before, the diﬀ  erent types of breast cancer 
probably reﬂ  ect a distinct cell of origin present along the 
hierarchical organization of the normal mammary gland. 
Indeed, the luminal subtype is characterized by high 
expression of genes of the luminal compartment, 
including estrogen receptor alpha (ERα), cytokeratin 18, 
the transcription factor GATA3 and estrogen-regulated 
genes; this group is further subdivided into type A and 
type B, which diﬀ  er for the level of expression of ERα, the 
proliferation index (assessed by Ki67 staining), and the 
clinical outcome [35]. Th   e Her2 subtype is characterized 
by overexpression of the Her2 protein on the cell 
membrane, due to genomic ampliﬁ  cation of the region 
17q22.24 that includes the genes coding for Her2 and 
growth factor receptor-bound protein 7. Th  e normal 
breast signature deﬁ   nes a group of tumors with high 
expression of genes of adipose cells and other non-
epithelial cell types, as well as low levels of luminal 
markers. Finally, tumors belonging to the basal-like sub-
group express high levels of basal markers, such as 
cytokeratins 5/14/17 and laminin, and do not express 
ERα, progesterone receptor and Her2. Notably, it was 
initially assumed that the cell of origin of this tumor 
subtype was to be found in the stem cells of the basal 
compartment. Recent gene expression proﬁ   ling of the 
diﬀ  erent subpopulations in the human normal mammary 
gland and analysis of tumors with basal-like features, 
however, showed that this tumor phenotype appears to 
be more similar to the gene signature derived from the 
luminal progenitor population [36].
Th  e molecular classiﬁ   cation of breast cancer has an 
important prognostic value: the single subtypes have 
diﬀ  erent prognosis and show diﬀ  erent responsiveness to 
speciﬁ  c therapies. Th  e luminal tumors are those with a 
better outcome and a wider possibility of treatment: ERα 
is preferentially expressed in terminally diﬀ  erentiated 
luminal cells and, accordingly, luminal tumors exhibit a 
diﬀ  erentiated morphology with almost benign features. 
More importantly, the mitogenic activity of estrogen can 
be counteracted by endocrine agents such as tamoxifene 
and aromatase inhibitors [37,38]. In the case of the Her2 
group, tumors are endowed with a more aggressive 
pheno  type, but overexpression of Her2 makes the 
majority of such tumors highly responsive to Her2 
inhibition obtained with the speciﬁ  c  monoclonal 
antibody trastuzumab (Herceptin) [39].
Among the diﬀ  erent subgroups, the basal-like breast 
cancers (BLBCs) are those that have the worst clinical 
outcome: they represent 15 to 20% of human breast 
cancer and are characterized by an aggressive phenotype 
with high histological grade, pushing borders, large areas 
of necrosis and high mitotic indexes. Th  e majority of 
BLBCs does not express hormone receptors (ERα and 
progesterone receptor) and is negative for Her2; they are 
therefore called triple-negative tumors [40,41]. Th  eir 
mole  cular features render these tumors especially 
diﬃ   cult to treat with anti-hormonal approaches; more-
over, the lack of understanding of the genes and processes 
involved in transformation and progression of this tumor 
subtype makes it diﬃ   cult to target with last-generation 
tailored therapies. As for conventional chemothera-
peutics, BLBCs appear to be more sensitive than luminal 
subtypes to neoadjuvant anthracycline-based regimens, 
which could be explained by the fact that anthracyclines 
work eﬃ   ciently on hyperproliferating cells and that the 
proliferation-related gene set is highly represented in this 
subtype; yet BLBCs have poor survival due to higher 
relapse rate following incomplete pathologic response 
[42]. In this scenario, the identiﬁ   cation of causative, 
targetable biomarkers for the basal subtype, which could 
be challenged for prospective therapies, remains an 
unmet clinical need.
Met and basal-like breast cancer
Together with patient-derived material, breast cancer cell 
lines have been utilized as tools to identify new markers 
for the study of breast tumor subtypes. Both genome-
wide expression proﬁ  ling and proteomic approaches led 
to the classiﬁ  cation of cell lines in two major clusters: the 
luminal group and the basal group. Similar to data 
obtained from surgical specimens, genes overexpressed 
in the luminal cluster include ERα, GATA3, cytokeratin 
19 and genes associated with ER-positive status, such as 
cytokeratin 8, cytokeratin 18 and mucin 1. Th  e basal 
cluster is typiﬁ   ed by high expression of cytokeratins 
5/14/17, integrin α6, integrin β4, CD44, CD10 and 
caveolin 1. Interest  ingly, these large-scale analyses allowed 
the identiﬁ  cation of new basal markers: together with 
other tyrosine kinases, including the epidermal growth 
factor receptor (EGFR) and c-Kit, Met emerged as one of 
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versus the luminal cluster [43,44].
Th   ese results have been conﬁ  rmed in tissue microarray-
based clinical studies on a large number of breast 
carcino  mas [44-47]. A cohort of 930 tumor samples, 
subdivided according to patient survival and lymph node 
status, was screened for expression of Met together with 
proteins known to be representative of the basal 
phenotype (cytokeratin 5, cytokeratin 6, caveolin 1, c-Kit, 
p63). High Met staining was found in tumors from 
deceased patients with highly invasive malignancies. 
Importantly, Met overexpression was consistently asso-
cia  ted with co-expression of basal markers, thus pin-
pointing Met as an additional constituent of the basal 
phenotype [45]. Similar ﬁ   ndings were obtained in an 
inde  pendent tissue microarray containing 1,600 speci-
mens from 547 patients with early breast cancer [44] and 
in a more limited subset of metastatic tumors [46].
Mechanistic insights
A mechanistic link between Met and BLBCs is high-
lighted by the observation that receptor overexpression 
correlates with high expression levels of the transcription 
factor Y-box binding protein-1 (YB-1). An oncogenic 
transcriptional/translational factor, YB-1 was originally 
identiﬁ  ed by screening an expression library for DNA-
binding proteins able to interact with the EGFR enhancer 
and with the Her2 promoter region [48]. A recent survey 
of candidate DNA-binding regions showed that YB-1 can 
bind to more than 6,000 promoters, among which 
promoters of kinases and growth factor receptors are 
highly repre  sented [49]. YB-1 is highly expressed in more 
than 70% of basal-like cancers, and its expression 
correlates with poor survival and high risk of relapse [50]. 
YB-1 is also expressed in normal mammary bipotent 
progenitor cells, but the level of the protein is much 
lower than that observed in tumors. Th  is diﬀ  erential 
expression is in line with a functional role for this 
transcription factor in tumor onset and progression.
Among the transcriptional targets of YB-1 there are 
several genes representative of the basal-like signature, 
including Met [49,51]. Chromatine immunoprecipitation 
analysis indicated that YB-1 binds directly to the Met 
promoter in a region that resides –1,080 bp from the 
translational starting site, thus driving Met expression. 
YB-1 and Met are both highly expressed in cell lines 
belonging to the basal cluster, and the downmodulation 
of YB-1 produces a reduction in the levels of Met, 
together with an impairment of cell proliferation and 
anchorage-independent growth. Neither YB-1 nor the 
Met gene appeared to be ampliﬁ  ed in basal cell lines, 
indicating that the main mechanism leading to over-
expression of both molecules is probably based on 
transcriptional/translational regulation [49].
Met and mouse models of basal-like breast cancer
Recently, two diﬀ   erent mouse models of conditional 
expression of oncogenic Met variants in the mammary 
gland demonstrated a causal role for Met in the onset of 
diverse types of mammary tumors, including BLBCs. In 
the ﬁ  rst model, the oncogenic mutant of Met, containing 
activating missense mutations within the tyrosine kinase 
domain, was knocked-in downstream from the Met 
endogenous promoter [52]; in the second model, trans-
forming isoforms of Met were transgenically expressed in 
the mammary epithelium under the control of the mouse 
mammary tumor virus promoter [53]. Oncogenic Met 
knock-in mice developed a spectrum of mammary 
cancers (solid adenocarcinomas, adenosqua  mous carci-
nomas, and myoepitheliomas), with some of them 
displaying histological, cytogenetic, and phenotypic 
charac  teristics typical of basal-like cancers, such as 
cytokeratin 5 expression and absence of progesterone 
receptor and Her2 expression. Similarly, transgenic mice 
with mouse mammary tumor virus promoter-driven 
expression of mutant Met developed tumors with a high 
degree of morphological heterogeneity, including solid/
luminal features and lesions with papillary, scirrhous, 
adenosquamous, or spindle-cell phenotypes. Gene 
expression proﬁ  ling for this latter mixed-pathology group 
revealed that such tumors have an enrichment of basal 
markers as well as genes associated with epithelial–
mesenchymal transition; for instance, Snail [53].
Analysis of Met expression in a cohort of human breast 
cancer samples showed that tumors with the highest 
levels of Met correlate with the basal subtypes, and breast 
cancers with a transcriptional signature indicative of Met 
activation mainly fall within the basal cluster. Among 
these tumors, those with active Met expression proﬁ  ling 
had a worse prognosis and a shorter disease-free survival 
[52]. Th  ese transcriptional data have been recently 
corroborated by genome-wide copy number analysis in 
BLBC cell lines: although focal ampliﬁ  cation of MET was 
not detected, speciﬁ   c enrichment of the HGF/Met 
pathway was reﬂ  ected in frequent copy number gains and 
overexpression of key adapter molecules and downstream 
signal transducers [54].
In sum, studies performed in cell lines, in patient-
derived material, and in animal models provide a clear 
indication that Met is preferentially expressed (or is 
mainly active) in BLBCs with respect to other subtypes of 
breast cancer. While this is certainly true, it should be 
noted that Met overexpression can be observed 
sporadically also in nonbasal-like tumors: for example, 
increased levels of Met are detectable in some cases of 
Her2-positive and ER-positive mammary carcinomas 
[52,53]. Something similar also applies to other tyrosine 
kinase receptors, including EGFR and c-Kit: their 
expression strongly correlates with BLBCs, but these 
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subtype [40]. Indeed, when taken individually, none of 
the markers of the basal cluster can function as 
independent predictors. Th  ese markers do, however, 
comprehensively deﬁ   ne an algorithm that signiﬁ  cantly 
segregates BLBCs versus other breast cancer entities.
Met, BRCA1 mutated cancer and the basal 
phenotype
Th   e basal-like group also includes a type of familial breast 
cancer that arises in BRCA1 mutation carriers. Th  e 
presence of germline BRCA1 mutations increases the risk 
of developing breast cancer and ovarian cancer in young 
women [55]. Th  e pathologic and molecular features of 
breast cancers arising in BRCA1 mutation carriers 
resemble those observed in the basal-like subtype: such 
tumors have a high histological grade, high proliferation 
indexes and pushing borders, and lack ERα, progesterone 
receptor and Her2 expression [56,57].
The molecular function of BRCA1
One of the main activities of BRCA1 involves the 
regulation of DNA double-strand break repair through 
the process of homologous recombination. Tumor cells 
that lack BRCA1 expression are hence relatively sensitive 
to DNA-damaging agents [58]. Th   ese cells are particularly 
responsive to chemical inhibition of poly(ADP-ribose) 
polymerase, which leads to the accumulation of DNA 
single-strand breaks that are then converted into DNA 
double-strand breaks during replication [59-61]. In 
normal cells, the DNA double-strand breaks are ﬁ  xed by 
repair mechanisms involving BRCA1; in cells lacking 
BRCA1, these lesions are repaired by error-prone 
systems, such as nonhomologous end joining, with the 
consequent accumulation of mutations and complex 
chromosomal rearrangements that ultimately lead to cell 
death [62].
Tumors arising in BRCA1-mutated patients are charac-
terized by the presence of somatic inactivating mutations 
of p53 [63,64]. Genomic instability caused by BRCA1 loss 
would normally lead to cell-cycle arrest through the p53-
mediated DNA damage checkpoint, and eventually to 
apoptosis. Th  e concomitant loss of function of p53 
aﬀ  ords cells the ability to bypass this checkpoint block 
and to continue unscheduled proliferation in the face of 
severe chromosomal instability. In this condition, the 
ensuing occurrence of secondary lesions is likely to 
contribute to full-blown neoplastic transformation [65].
Met, BRCA1 and mouse models of basal-like breast cancer
Met overexpression has been associated with experi-
mental tumors arising in a BRCA1 mutated context, 
speciﬁ  cally in a mouse model in which BRCA1 and p53 
were conditionally deleted in the mammary epithelium 
[65]. A genome-wide screening of tumors developed in 
these mice revealed that the most common genetic 
alteration was ampliﬁ   cation of the Met locus (73% of 
cases). As a consequence, these tumors expressed high 
levels of Met mRNA and protein. Th  e  ampliﬁ  cation was 
associated with extra-chromosomal double minutes; 
these are unstable genomic elements that were detected 
in vivo by ﬂ  uorescence in situ hybridization analysis of 
mouse-derived tumors but were rapidly lost in primary 
cultures, probably because double minutes are main-
tained only in the presence of in vivo selection pressures 
within the breast microenvironment.
It is noteworthy that Met ampliﬁ  cation in the form of 
extrachromosomal double minutes is also a primary 
alteration in the mutant Met knock-in mice that develop 
basal-like breast tumors [52]. Together, these ﬁ  ndings 
suggest that Met ampliﬁ  cation may be a common event 
in murine mammary tumorigenesis. Focal ampliﬁ  cation 
of the MET gene, however, is not a common ﬁ  nding in 
human breast cancer: interphase ﬂ  uorescence  in situ 
hybridization performed on a human breast cancer tissue 
microarray did not reveal any ampliﬁ  cation of the Met 
genomic locus [65], and this genetic alteration has not so 
far been reported for BRCA1 mutation carriers. A more 
frequent occurrence is low-grade polysomy (three to ﬁ  ve 
copies) of chromosome 7 – where the MET locus resides – 
which is detected in approximately 25% of human ductal 
inﬁ  ltrating carcinomas [66].
Met and epidermal growth factor receptor in basal-like 
breast cancer
Another tyrosine kinase that phenotypically marks basal-
like breast tumors is EGFR. Similar to Met, EGFR is 
highly expressed in the majority of BLBCs in vivo and 
exerts proliferative and anti-apoptotic functions in 
cultured basal-like breast cancer cells [43]. In preclinical 
studies, EGFR inhibition can potentiate cisplatin-induced 
apoptosis in cultured basal-like breast cells [67].
Clinical trials with epidermal growth factor receptor inhibitors
Based on these observations, clinical trials have been 
designed to study the eﬀ   ect of EGFR inhibition in 
patients with BLBC. Two studies completed to date have 
provided interlocutory results. TBCRC 001 was a 
randomized phase II trial evaluating the role of EGFR 
inhibition for triple-negative metastatic breast cancer. In 
this study, eligible women received the anti-EGFR mono-
clonal antibody cetuximab combined with carboplatin, or 
received cetuximab alone with a planned crossover to 
carboplatin at progression. Cetuximab alone showed a 
low response rate and this trial arm was closed before 
time; response to the combination of cetuximab plus 
carboplatin was 17%, with clinical beneﬁ  t seen in 29% of 
a pretreated population [68]. A similar study examining 
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showed a modestly higher response rate (from 30 to 49%) 
with the cetuximab combination [68].
Th  ese interim data together indicate that targeted 
therapies against EGFR in breast tumors appear to be 
poorly eﬀ  ective with respect to other types of cancer in 
which EGFR deregulation has been documented, such as 
lung cancer and colon cancer [69-71]. Th  is lack of eﬀ  ect 
could be due, at least in principle, to the presence of 
concomitantly active signal transduction pathways ema  na-
ting from other tyrosine kinase receptors, including Met.
The Met–epidermal growth factor receptor connection
Several pieces of evidence point to an intimate relation-
ship between EGFR and Met signaling, both in 
physio  logical settings, such as mammary gland morpho-
genesis [72], and in pathologic conditions, including 
cancer progression and resistance to targeted therapies. 
In nonsmall-cell lung carcinomas, for example, the onset 
of secondary resistance to EGFR inhibition relies, among 
other things, on the acquisition of MET gene ampliﬁ  -
cation and consequent protein over  expres  sion, which 
leads to activation of signal transduction cascades that 
compensate for EGFR blockade and sustain tumor 
maintenance [73-75]. Something similar might also occur 
in mammary tumors. Met and EGFR are both over-
expressed in breast cancer cell lines endowed with a 
basal-like subtype molecular proﬁ  le [42]. In this context, 
resistance to the EGFR inhibitor geﬁ  tinib occurs because 
EGFR is trans-phosphorylated via a Met/Src-mediated 
Table 2. Summary of HGF/Met inhibitors currently in clinical trials
     Phase  of
Agent Type  Targets  development  Comments
AMG102 (Amgen)  Antibody  Human HGF  Phase 1/2  Tested in small-cell lung cancer, metastatic colorectal 
        carcinoma, malignant glioma, prostate cancer, renal cell 
        carcinoma, gastric or esophagogastric junction cancer, 
        mesothelioma, ovarian cancer or peritoneal cancer
SCH900105  Antibody  Human HGF  Phase 1/2  Tested in nonsmall-cell lung cancer
(Aveo Pharmaceuticals)
MetMab (Genentech)  Monovalent antibody  Human Met  Phase 1/2  Tested in nonsmall-cell lung cancer
ARQ197 (ArQule)  Selective small-molecule   Met  Phase 1/2  Tested in nonsmall-cell lung cancer, metastatic
  inhibitor, non-ATP       colorectal carcinoma, pancreatic adenocarcinoma, 
  competitive      hepatocellular carcinoma, gastric carcinoma, germ cell 
        tumors, renal cell carcinoma, alveolar soft part sarcoma, 
        clear cell sarcoma
JNJ-38877605  Selective small-molecule  Met  Phase 1 
(Johnson and Johnson)  inhibitor, ATP competitive
EMD-1214063  Selective small-molecule   Met  Phase 1 
(EMD Serono)  inhibitor, ATP competitive 
INCB-028060 (Incyte)  Selective small-molecule   Met  Phase 1 
  inhibitor, ATP competitive 
MK-8033 (Merck)  Selective small-molecule   Met, Ron  Phase 1 
  inhibitor, ATP competitive  (10-fold less active) 
PF-02341066 (Pfi  zer)  Multikinase inhibitor,   Met, ALK  Phase 1/2  Tested in nonsmall-cell lung cancer
 ATP  competitive
GSK-1363089/XL880  Broad-spectrum kinase   Met, Ron, VEGFR1  Phase 1/2  Tested in gastric cancer, nonsmall-cell lung cancer,
(Exelixis)  inhibitor, ATP competitive  to VEGFR3, PDGFR,     papillary renal-cell carcinoma
    Kit, Flt-3, Tie-2    
BMS-907351/XL184  Broad-spectrum kinase   Met, VEGFR2, Ret,   Phase 1/2/3  Tested in medullary thyroid cancer, nonsmall-cell lung
(Exelixis)  inhibitor, ATP competitive  Kit, Flt-3, Tie-2    carcinoma, glioblastoma, astrocytic tumors
MP470 (SuperGen)  Broad-spectrum kinase   Met, Ret, Rad51,   Phase 1b  Tested in neuroendocrine tumors, lung cancer, 
  inhibitor, ATP competitive  mutant forms of Kit,     triple-negative breast cancer
   PDGFR,  Flt-3
MGCD265 (Methylgene)  Broad-spectrum kinase   Met, Ron, VEGFR1  Phase 1 
  inhibitor, ATP competitive  to VEGFR3, Kit, 
   Flt-3,  Tie-2 
MK-2461  Broad-spectrum kinase   Met, KDR, FGFR1  Phase 1 
  inhibitor, ATP competitive  to FGFR3, Flt-1,   completed
   Flt-3,  Flt-4 
FGFR, fi  broblast growth factor receptor; HGF, hepatocyte growth factor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor 
receptor.
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Page 7 of 10signaling pathway. Accordingly, cancer cell proliferation 
can be impaired by combined neutralization of EGFR and 
Met signals [76].
Together with Met and EGFR, other tyrosine kinase 
receptors have been reported to be overexpressed in 
basal-like breast carcinoma: among these prominent 
druggable targets are c-Kit and the ﬁ  broblast  growth 
factor receptor. High levels of c-Kit are preferentially 
found in BRCA1-associated basal-like tumors; of note, c-
Kit mRNA expression appears to be already twofold 
higher in preneoplastic BRCA1 mutation-associated 
breast tissue versus non-BRCA1/2 breast tissue, suggest-
ing that c-Kit upregulation may be an early event in 
BRCA1-driven tumorigenesis [36]. Fibroblast growth 
factor receptor has been shown to be ampliﬁ  ed at the 
genomic level in two BLBC cell lines; both lines undergo 
apoptosis following pharmacologic or RNA interference-
mediated inactivation of the kinase [54].
Conclusions
Some of the genes described as belonging to the diﬀ  erent 
subtypes of breast cancer have been reported to play 
important roles in the deﬁ  nition of a speciﬁ  c cell lineage 
in normal mammary development and to be deregulated 
in the tumors that recapitulate the characteristics of that 
speciﬁ   c lineage. For example, the transcription factor 
GATA3 mediates luminal diﬀ   erentiation in gland 
development and GATA3 deﬁ  ciency leads to a block in 
luminal terminal diﬀ  erentiation, with an expansion of the 
progenitor compartment [34,77]. Consistently, in the 
tumor counterpart, GATA3 is highly expressed in the 
luminal subtypes [27,78].
When applying this line of thinking to the HGF/Met 
system, one could speculate that the correlation between 
Met expression and basal markers reﬂ  ects a precise Met 
function in physiological gland development; namely, in 
the deﬁ  nition of a poorly diﬀ  erentiated basal compart  ment 
and/or in the negative regulation of luminal terminal 
diﬀ  erentiation. Future work is needed to address the role 
of Met in mammary lineage determination and to analyze 
whether Met activation can trigger a genetic/molecular 
program that dictates commitment to one speciﬁ  c 
mammary subpopulation with respect to the others.
While the association between high Met expression 
and human basal cancers is now well deﬁ  ned,  the 
causative role for Met in the onset and/or maintenance of 
BLBCs is less clear: mice in which active forms of Met are 
speciﬁ   cally expressed in the mammary epithelium 
develop breast carcinomas with basal-like features, but 
they are also prone to tumors with phenotypic and 
molecular characteristics other than those of BLBCs 
[52,53]. To tackle this issue at the clinical level, it will be 
interesting to explore whether targeting of Met in basal-
like cancer will have therapeutic value. Several anti-Met 
antibodies and small-molecule Met inhibitors have been 
recently developed, and many of them are now being 
tested in phase 1 and phase 2 clinical trials [79-81] 
(Table  2). Th  ese agents will probably prove useful in 
combination with other therapies, including EGFR, c-Kit, 
and ﬁ   broblast growth factor receptor inhibitors. At 
present, the availability of mouse models that develop 
Met-driven basal-like breast tumors provides a useful 
experimental platform to assay the eﬃ   cacy  of  Met 
inhibition in the preclinical setting and to guide future 
intervention in human patients.
Abbreviations
BLBC, basal-like breast cancer; EGFR, epidermal growth factor receptor; ERα, 
estrogen receptor alpha; HGF, hepatocyte growth factor; YB-1, Y-box binding 
protein-1.
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